MX2024002887A - Metodos para tratar enfermedades neurodegenerativas. - Google Patents

Metodos para tratar enfermedades neurodegenerativas.

Info

Publication number
MX2024002887A
MX2024002887A MX2024002887A MX2024002887A MX2024002887A MX 2024002887 A MX2024002887 A MX 2024002887A MX 2024002887 A MX2024002887 A MX 2024002887A MX 2024002887 A MX2024002887 A MX 2024002887A MX 2024002887 A MX2024002887 A MX 2024002887A
Authority
MX
Mexico
Prior art keywords
methods
neurogenerative diseases
treating
forms
treating neurogenerative
Prior art date
Application number
MX2024002887A
Other languages
English (en)
Spanish (es)
Inventor
Xiaoyan Zhang
Scott J Barraza
Jeffrey K Trimmer
Yong Yu
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2024002887A publication Critical patent/MX2024002887A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024002887A 2021-09-07 2022-09-06 Metodos para tratar enfermedades neurodegenerativas. MX2024002887A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163260944P 2021-09-07 2021-09-07
PCT/US2022/075969 WO2023039370A1 (en) 2021-09-07 2022-09-06 Methods for treating neurogenerative diseases

Publications (1)

Publication Number Publication Date
MX2024002887A true MX2024002887A (es) 2024-05-28

Family

ID=85506888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002887A MX2024002887A (es) 2021-09-07 2022-09-06 Metodos para tratar enfermedades neurodegenerativas.

Country Status (7)

Country Link
US (1) US20240374602A1 (https=)
EP (1) EP4398988A4 (https=)
JP (1) JP2024533264A (https=)
CN (1) CN118401243A (https=)
CA (1) CA3231001A1 (https=)
MX (1) MX2024002887A (https=)
WO (1) WO2023039370A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
WO2012012656A2 (en) * 2010-07-21 2012-01-26 University Of South Florida Materials and methods for treating neurodegenerative diseases
CN115209955A (zh) * 2019-12-12 2022-10-18 Ptc医疗公司 治疗家族性自主神经功能障碍的化合物

Also Published As

Publication number Publication date
EP4398988A4 (en) 2025-07-09
JP2024533264A (ja) 2024-09-12
EP4398988A1 (en) 2024-07-17
CN118401243A (zh) 2024-07-26
CA3231001A1 (en) 2023-03-16
WO2023039370A1 (en) 2023-03-16
US20240374602A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
CO2019011873A2 (es) Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats
MX2024002887A (es) Metodos para tratar enfermedades neurodegenerativas.
BR112017001565A2 (pt) ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto?
PE20191499A1 (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
BR112022014149A2 (pt) Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)-1h-pirazolo[3,4-d]pirimidina-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrila
EA202192170A1 (ru) ТИЕНО[3,2-b]ПИРИДИН-7-АМИНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ СЕМЕЙНОЙ ВЕГЕТО-СОСУДИСТОЙ ДИСТОНИИ
JOP20190143A1 (ar) مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز
MX373865B (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
UY36176A (es) Formas cristalinas de (2r, 5s, 13ar)-8-hidroxi-7,9- dioxo- n-(2,4,6 - trifluorobencil)-2,3,4,5,7,9,13,13a -octahidro -2,5- metanopirido[1?,2?,4,5]pirazino[2,1-b][1,3]oxazapina- 10-carboxamida
BR112016012734A8 (pt) composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
MX2024002886A (es) Metodos para tratar enfermedades neurodegenerativas.
CL2020003227A1 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak.
MX387025B (es) Compuestos de anillo de siete miembros de pirimidina
MX390505B (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
UY40111A (es) Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas
BR112019008163A2 (pt) compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
MX2024002888A (es) Metodos para tratar enfermedades neurodegenerativas.
AU2019296118A8 (en) Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor
MX394320B (es) Formas solidas de compuestos de 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituidos
DOP2025000144A (es) Formas cristalinas de (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluoro–metil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida
CL2021001447A1 (es) Formas cristalinas a, b, d, i de 1–(6–((6–((1r)–1–hidroxietil)–8–isopropilamino)pirido[3,4–d]pirimidin–2–il)amino)–3–piridil)piperazin–2–ona; composición farmacéutica que las comprende; y su uso para tratar artritis reumatoide, arteriosclerosis, entre otras enfermedades (divisional solicitud 201901420).